Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP-1 deregulation in multiple sclerosis

1 Oct 2019

Abstract excerpt

BACKGROUND: Poly (ADP-ribose) polymerase 1 (PARP-1) plays pivotal roles in immune and inflammatory responses. Accumulating evidence suggests PARP-1 as a promising target for immunomodulation in multiple sclerosis and natalizumab-associated progressive multifocal leukoencephalopathy. OBJECTIVE: This study explores expression of PARP-1 and downstream effectors in multiple sclerosis and during natalizumab treatment....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Sclerosis Research Studies
Share to PARP inhibition in cancer therapy
Share to Polyomavirus and related diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31897308
DOI: 10.1177/2055217319894604

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP-1 deregulation in multiple sclerosisPMID 31897308Read ↗

Therapeutic Potentials of Poly (ADP‐Ribose) Polymerase 1 (PARP1) Inhibition in Multiple Sclerosis and Animal Models: Concept RevisitingSemantic proximity Read ↗

PARP-1 Deficiency Increases the Severity of Disease in a Mouse Model of Multiple SclerosisSemantic proximity Read ↗

Poly (ADP-Ribose) polymerase 1 and parthanatos in neurological diseases: From pathogenesis to therapeutic opportunitiesSemantic proximity Read ↗

Existing Evidence for the Repurposing of PARP-1 Inhibitors in Rare Demyelinating DiseasesSemantic proximity Read ↗

Poly(ADP-ribose) Polymerase 1 Deficiency Attenuates Amyloid Pathology, Neurodegeneration, and Cognitive Decline in a Familial Alzheimer’s Disease ModelSemantic proximity Read ↗

Pharmacologic inhibition of MIF nuclease: A new treatment paradigm to treat cell deathSemantic proximity Read ↗

NF-&#954;B, a Potential Therapeutic Target for the Treatment of Multiple SclerosisSemantic proximity Read ↗

IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and AiolosSemantic proximity Read ↗

Nuclear Factor κB (NF-κB)–Mediated Inflammation in Multiple SclerosisSemantic proximity Read ↗

A nuclease that mediates cell death induced by DNA damage and poly(ADP-ribose) polymerase-1.Semantic proximity Read ↗

Poly(ADP-Ribose) Polymerases in Host-Pathogen Interactions, Inflammation, and ImmunitySemantic proximity Read ↗

The Role of Poly(ADP‐ribose) Polymerase‐1 in Rheumatoid ArthritisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.